Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma
- 1 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 31 (1), 98-101
- https://doi.org/10.1093/icvts/ivaa059
Abstract
High-grade and poorly differentiated thymic neuroendocrine carcinoma is the rarest entity in thymic epithelial tumours. The aim of this study is to report survival data in a multi-institutional database in comparison to data in the literature. Retrospective chart review was performed on the basis of our multi-institutional database to identify patients undergoing the resection of poorly differentiated thymic neuroendocrine carcinoma between 1991 and 2018. Relevant factors were extracted, and survival analysis was performed using the Kaplan-Meier method. Twenty-one patients were identified. Five-year overall survival and recurrence-free survival were 64.6% and 51.8%, respectively. Twelve (57.1%) patients had recurrences. Due to the scarcity of data reported in the literature, our data may be used as a standard in high-grade and poorly differentiated thymic neuroendocrine carcinoma.This publication has 3 references indexed in Scilit:
- Treatment, prognostic markers, and survival in thymic neuroendocrine tumorsMedicine, 2017
- Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databasesThe Journal of Thoracic and Cardiovascular Surgery, 2015
- Neuroendocrine Carcinomas (Carcinoid Tumor) of the ThymusAmerican Journal of Clinical Pathology, 2000